Trial Profile
Visual outcomes of treatment with Ranibizumab and Dexamethasone in patients with myopic choroidal neovascularisation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 May 2017
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Ranibizumab (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- 16 May 2017 New trial record